If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT03327740","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"http://","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"None","acronym":"","allocation":"","arm_groups":[{"arm_group_label":"Subjects on DTG based ARV with ABC","arm_group_description":"These are subjects who begin a DTG based ARV regimen that includes ABC","arm_type":""},{"arm_group_label":"Subjects that start DTG based ARV regimen but without ABC","arm_group_description":"These are subjects who begin a DTG-based ARV regimen that does not contain ABC","arm_type":""},{"arm_group_label":"Subjects on other integrase inhibitor based regimen with ABC","arm_group_description":"These are subjects who begin other integrase inhibitor based regimens (RAL and EGV) that contains ABC","arm_type":""},{"arm_group_label":"Subjects on other integrase inhibitor based regimen but no ABC","arm_group_description":"These are subjects that start non-ABC containing RAL or EGV based regimens","arm_type":""},{"arm_group_label":"Subjects that start any other DTG based ARV regimen","arm_group_description":"These are subjects who begin any other DTG based ARV regimen that will include DTG as monotherapy or two-drug regimens","arm_type":""}],"assignment":"","brief_summary":"Dolutegravir (DTG) is recommended for both treatment-naïve and treatment-experienced, HIV infected adults and paediatric subjects aged 12 years and older and weighing at least 40 kg. One case of suspected DTG hypersensitivity (HSR) reaction from among over 1500 subjects exposed to the drug at the time of submission in 4Q2012, has been identified; this subject experienced a diffuse maculopapular rash with fever and elevated liver enzymes. Isolated rash was uncommon in the DTG programme with less than 1% of clinical trial subjects experiencing treatment related rash. The pharmacovigilance strategy for DTG and DTG-containing products is to implement a post-marketing risk management program to further quantify the risk of HSR and compare it to that of other integrase inhibitors, and to possibly determine associated risk factors. In addition, the post-authorization safety study will monitor and compare hepatotoxicity and severe skin rash following initiation of DTG or other integrase inhibitor (raltegravir (RAL) or elvitegravir (EGV) based antiretroviral regimens (ARV). Further to be able to distinguish the above symptoms and reactions caused by DTG or the other integrase inhibitor regimen from that of abacavir (ABC), known to cause hypersensitivity reaction, the integrase inhibitor groups will be compared in combinations with and without ABC. This five year-long safety study will be conducted through collaboration with EuroSIDA, a well established prospective observational cohort study of more than 18,200 subjects followed in 107 hospitals in 31 European countries, plus Israel and Argentina. This is a five year-long non-interventional prospective cohort study nested within the EuroSIDA study. The study population will include HIV positive subjects over the age of 16 years from EuroSIDA clinical sites, who are new users of DTG or other integrase inhibitors with and without ABC. Following initiation of DTG with ABC based antiretroviral regimen or DTG without ABC or regimens containing other integrase inhibitors (RAL, EGV) with or without ABC or any other DTG based ARV regimen as monotherapy or two-drug regimens, the study will aim to a) Monitor and compare hypersensitivity reaction, b) Monitor and compare hepatotoxicity, and c) Monitor and compare severe skin rash among all subjects discontinuing DTG or other integrase inhibitor regimens for any reason.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus I","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:32:15","criteria":"Inclusion Criteria: - New users of DTG or users of other integrase inhibitor regimens (RAL and EGV) Exclusion Criteria: - None","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"","display_phase_internal":"","display_status":"Ongoing","display_status_internal":"RECSTATUS_O_ONGOING","endpoint":"","enrollment":"1","exclusion":"","gender":"All","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"84a62b56-5942-5c39-9196-0ab3aa58ead5","internal":{"content":null,"contentDigest":"6b5d88d35f56596886f71ecdc3afd3b2","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - New users of DTG or users of other integrase inhibitor regimens (RAL and EGV) Exclusion Criteria: - None","interventions":[{"arm_group_label":"Subjects on DTG based ARV with ABC","intervention_description":"ARV regimens containing DTG and ABC","intervention_name":"DTG based ARV regimen with ABC","intervention_type":"Drug"},{"arm_group_label":"Subjects that start DTG based ARV regimen but without ABC","intervention_description":"DTG based ARV regimens that do not contain ABC","intervention_name":"DTG based ARV regimen without ABC","intervention_type":"Drug"},{"arm_group_label":"Subjects on other integrase inhibitor based regimen with ABC","intervention_description":"RAL or EGV based regimens containing ABC","intervention_name":"RAL or EGV based ARV regimens with ABC","intervention_type":"Drug"},{"arm_group_label":"Subjects on other integrase inhibitor based regimen but no ABC","intervention_description":"RAL or EGV based ARV regimens that do not contain ABC","intervention_name":"RAL or EGV based regimens without ABC","intervention_type":"Drug"},{"arm_group_label":"Subjects that start any other DTG based ARV regimen","intervention_description":"Any other DTG based ARV regimens including DTG as monotherapy or two-drug regimens.","intervention_name":"Any other DTG based ARV regimen as monotherapy","intervention_type":"Drug"}],"interventional_subtype":"","is_fda_regulated":false,"is_high_value":false,"is_ind_study":false,"keywords":["Hypersensitivity reactions (HSR)","HIV","Dolutegravir"],"last_follow_up_date":"06/30/2019 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"N/A","maximum_age":"N/A","minimum_age":"17","minimum_age_raw":"17 years","modified_date":"10/01/2018 22:34:40","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"None Retained","number_of_groups":"5","observational_study_design":"Cohort","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":"Prospective"},"official_title":"A Prospective Observational Cohort Study to Monitor and Compare the Occurrence of Hypersensitivity Reaction and Hepatotoxicity in Patients Receiving Dolutegravir (with and without Abacavir) or other Integrase Inhibitors (with or without Abacavir)","org_study_id":"201177","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Active, not recruiting - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"","primary_compl_date":"06/30/2019 00:00:00","primary_outcomes":[{"outcome_description":"Hypersensitivity reactions including fever, rash, gastrointestinal symptoms, constitutional symptoms, respiratory symptoms and eosinophilia will be summarized.","outcome_measure":"Number of subjects with occurrence of hypersensitivity reactions (HSR), of any grade","outcome_time_frame":"Up to 5 years","outcome_safety_issue":null},{"outcome_description":"Hepatic dysfunction will be indicated by liver chemistry tests","outcome_measure":"Number of subjects with hepatic dysfunction","outcome_time_frame":"Up to 5 years","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[{"id":"PRJ2203","id_type":"Other Identifier","id_domain":"GSK"}],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GSK"]},"start_date":"09/30/2014 00:00:00","study_type":"Observational","therapeutic_area":"","citations":[],"is_section_801":null}},"pageContext":{"studyId":"201177"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}